Asthma

LIBERTY ASTHMA QUEST Trial: Dupilumab Efficacy in Type 2 Asthma Patients on High-Dose ICS

LIBERTY ASTHMA QUEST Trial: Dupilumab Evidence Summary in Moderate-to-Severe Uncontrolled Asthma

Dupilumab improves clinical outcomes in patients with severe asthma compared to other biologics

LIBERTY ASTHMA QUEST Trial: Dupilumab Efficacy in Eosinophilic (≥500 cells/µL) and Allergic Asthma Subgroups

LIBERTY ASTHMA TRAVERSE Trial: Long-Term Safety and Efficacy of Dupilumab in Moderate-to-Severe Asthma

IL-4/IL-13 Dual Cytokine Signaling in Severe Asthma: Mechanistic Insights by Prof. Kenneth Chapman

Recognizing the key cytokines driving type 2 inflammation and understanding their profound impact on patients’ asthma burden is crucial.^1-3

IL-4, IL-13, AND IL-5 ARE DRIVERS OF SYSTEMIC TYPE 2 INFLAMMATION

Eosinophilic inflammation has multiple drivers^1,2

The Role of Mucus Plugging in Asthma and Its Clinical Burden

Understanding Airway Obstruction: The Role of Mucus Plugging in Asthmatic Disease

Assessing Pediatric Lung Function

Pediatric Management

Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction

VESTIGE study

VESTIGE Trial Results: Dupilumab in Type 2 Asthma

FeNO Is a Clinically Useful Biomarker of Type 2 Inflammation in Pediatric Patients With Asthma

What's possible when their Child's Asthma is under control?

What gives you confidence that Dupixent improves patients’ quality of life?

What is your experience with Dupixent in your practice?

Severe Asthma Biomarker's

Lung Function Decline and Exacerbation in Asthma

OCS Video

How do you choose the right Biologic for a particular Asthma patients?

FeNO Video

Clinical Remission Video

Consider Dupixent for Asthmatic patients with OCS use

Airway Hyperresponsiveness in Asthma

ON-TREATMENT ASTHMA REMISSION: MOVING BEYOND CONTROL

Discover a solution to control mixed Eosinophilic and Allergic Asthma

About Type 2 Inflammation – Asthma

Dupixent® (dupilumab) Mechanism of Action

Consider Dupixent for Asthmatic patients with high EOS